Now Reading: BDR Pharma buys majority stake in Acme Formulation’s oral care biz
-
01
BDR Pharma buys majority stake in Acme Formulation’s oral care biz
BDR Pharma buys majority stake in Acme Formulation’s oral care biz
The Story in Brief
BDR Pharma will acquire a controlling stake in Acme Formulation's oral solid formulations business and its subsidiaries from existing shareholders led by private equity firm PAG, the companies announced on Monday (9 November 2026). The transaction values the business at about Rs 2,370 crore ($250 million), according to sources close to the deal.
The acquisition adds complementary capabilities across thyroid products, female sex hormone products and general pharmaceuticals, aligning with BDR's growth priorities in oncology, critical care and women's healthcare. BDR Chairman Dharmesh Shah said the deal strengthens the company's CDMO platform and forms part of a larger growth roadmap.
Post-transaction, PAG and Acme founder Viral Shah will retain full ownership of Immacule, a sterile injectable-focused contract manufacturing business that recently commissioned a facility with capacity of over 200 million units per annum. BDR, backed by Multiples Private Equity, is targeting an IPO by 2027 and plans to invest about Rs 700 crore in organic and inorganic expansion.
Indian Opinion Analysis
All four outlets report the same facts in near-identical language, with The Hindu Business Line, The Economic Times, Livemint and The Hindu each attributing the Rs 2,370 crore valuation to unnamed sources and quoting the same executives. The uniform coverage reflects a standard company announcement, with no outlet adding independent scrutiny or divergent framing. Livemint alone includes the author's biographical note, irrelevant to the deal. The consistent straight reporting across sources leaves no material difference in stance, the key watch item is BDR's stated IPO timeline of 2027 and its planned Rs 700 crore investment.
Coverage: 4 sources, 4 neutral
Sources (4): thehindubusinessline.com (neutral report), economictimes.indiatimes.com (neutral report), livemint.com (neutral report), thehindu.com (neutral report)
This brief was synthesised by AI from the 4 sources linked above, so one read covers every framing they carry. Methodology and corrections.
